TaiwanJ Pharmaceuticals Co (ROCO:6549) ROCE % : -47.35% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is TaiwanJ Pharmaceuticals Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. TaiwanJ Pharmaceuticals Co's annualized ROCE % for the quarter that ended in Dec. 2023 was -47.35%.

TaiwanJ Pharmaceuticals Co ROCE % Historical Data

The historical data trend for TaiwanJ Pharmaceuticals Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TaiwanJ Pharmaceuticals Co ROCE % Chart

TaiwanJ Pharmaceuticals Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

0.72

-25.81

-6.06

-78.27

-5.35

TaiwanJ Pharmaceuticals Co Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-20.23	-12.02	-146.29	36.25	-47.35

TaiwanJ Pharmaceuticals Co ROCE % Calculation

TaiwanJ Pharmaceuticals Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-3.749	/	( ( (79.789 - 7.015)	+	(73.558 - 6.146) )	/ 2 )
	=	-3.749	/	( (72.774	+	67.412)	/ 2 )
	=	-3.749	/	70.093
	=	-5.35 %

TaiwanJ Pharmaceuticals Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-36.116	/	( ( (88.752 - 3.612)	+	(73.558 - 6.146) )	/ 2 )
	=	-36.116	/	( ( 85.14	+	67.412 )	/ 2 )
	=	-36.116	/	76.276
	=	-47.35 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

TaiwanJ Pharmaceuticals Co (ROCO:6549) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

TaiwanJ Pharmaceuticals Co ROCE % Related Terms

Thank you for viewing the detailed overview of TaiwanJ Pharmaceuticals Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

TaiwanJ Pharmaceuticals Co (ROCO:6549) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TaiwanJ Pharmaceuticals Co Ltd (ROCO:6549) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Rm. D207, Number 2, Sec.2, ShengYi Road, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei, TWN, 30261

Website

http://www.taiwanj.com

TaiwanJ Pharmaceuticals Co Ltd is a Taiwan based specialty pharmaceutical company focused on small molecules for unmet medical needs like chronic organ inflammation of metabolic, autoimmune and infectious etiologies. It is also involved in developing novel chemical entities (NCEs) for chronic liver diseases and allergy/asthma.

TaiwanJ Pharmaceuticals Co (ROCO:6549) Headlines

No Headlines